Secreted soluble amyloid-β 1–37 (Aβ37) peptide is one of the prominent Aβ forms next to Aβ40, and is found in cerebrospinal fluid (CSF) and blood. Recent studies have shown the importance of quantitation of CSF Aβ37 levels in combination with Aβ38, Aβ40, and Aβ42 to support the diagnosis of patients with probable Alzheimer’s disease (AD), and the value of antibody to Aβ37 to facilitate drug discovery studies. However, the availability of reliable and specific monoclonal antibody to Aβ37 is very limited. Our aims were: 1) to generate and partially characterize rabbit monoclonal antibody (RabmAb) to Aβ37, and 2) to determine whether the antibody detects changes in Aβ37 levels produced by a γ-secretase modulator (GSM). Our generated RabmAb to Aβ37 was found to be specific to Aβ37, since it did not react with Aβ36, Aβ38, Aβ39, Aβ40, and Aβ42 in an ELISA or immunoblotting. The epitope of the antibody was contained in the seven C-terminal residues of Aβ37. The antibody was sensitive enough to measure CSF and plasma Aβ37 levels in ELISA. Immunohistological studies showed the presence of Aβ37-positive deposits in the brain of AD, and Down syndrome persons diagnosed with AD. Our studies also showed that the antibody detected Aβ37 increases in CSF and brains of rodents following treatment with a GSM. Thus, our antibody can be widely applied to AD research, and in a panel based approach it may have potential to support the diagnosis of probable AD, and in testing the effect of GSMs to target AD.
BiblM, GallusM, WelgeV, EsselmannH, WolfS, RütherE, WiltfangJ (2012) Cerebrospinal fluid amyloid-β 2-42 is decreased in Alzheimer’s, but not in frontotemporal dementia. J Neural Transm119, 805–813.
9.
SchiebH, KratzinH, JahnO, MobiusW, RabeS, StaufenbielM, WiltfangJ, KlafkiHW (2011) Beta-amyloid peptide variants in brains and cerebrospinal fluid from amyloid precursor protein (APP) transgenic mice: Comparison with human Alzheimer amyloid. J Biol Chem286, 33747–33758.
10.
MooreBD, ChakrabartyP, LevitesY, KukarTL, BaineAM, MoroniT, LaddTB, DasP, DicksonDW, GoldeTE (2012) Overlapping profiles of Aβ peptides in the Alzheimer’s disease and pathological aging brains. Alzheimers Res Ther4, 18–33.
11.
StruyfsH, Van BroeckB, TimmersM, FransenE, SleegersK, Van BroeckhovenC, De DeynPP, StrefferJR, MerckenM, EngelborghsS (2015) Diagnostic accuracy of cerebrospinal fluid amyloid-β isoforms for early and differential dementia diagnosis. J Alzheimers Dis45, 813–822.
12.
CzirrE, CottrellBA, LeuchtenbergerS, KukarT, LaddTB, EsselmannH, PaulS, SchubenelR, TorpeyJW, PietrizkCU, GoldeTE, WiltfandT, BaumannK, KooET, WeggenS (2008) Independent generation of Aβ42 and Aβ38 peptide species by α-secretase. J Biol Chem283, 17049–17054.
13.
BorgegardT, JuréusA, OlssonF, RosqvistS, SabirshA, RotticciD, PaulsenK, KlintenbergR, YanH, WaldmanM, StrombergK, NordJ, JohanssonJ, RegnerA, ParpalS, MalinowskyD, RadesaterAC, LiT, SinghR, ErikssonH, LundkvistJ (2012) First and second generation γ-secretase modulators (GSMs) modulate amyloid-β (Aβ) peptide production through different mechanisms. J Biol Chem287, 11810–11819.
14.
RogersK, FelsensteinKM, HrdlickaL, TuZ, AlbayyaF, LeeW, HoppS, MillerMJ, SpauldingD, YangZ, HodgdonH, NolanS, WenM, CostaD, BlainJF, FreemanE, De StrooperB, VulstekeV, ScrocchiL, ZetterbergH, PorteliusE, Hutter-PaierB, HavasD, AhlijanianM, FloodD, LeventhalL, ShapiroG, PatzkeH, ChesworthR, KoenigG (2012) Modulation of gamma-secretase by EVP-0015962 reduces amyloid deposition and behavioral deficits in Tg2576 mice. Mol. Neurodegener7, 61–79.
15.
SoaresHD, GasiorM, ToynJH, WangJS, HongQ, BerishaF, FurlongMT, RaybonJ, LentzKA, SweeneyF, ZhengN, AkinsanyaB, BermanRM, ThompsonLA, OlsonRE, MorrisonJ, DrexlerDM, MacorJE, AlbrightCF, AhlijanianMK, AbuTarifM (2016) The gamma secretase modulator, BMS-932481, modulates Aβ peptides in the plasma and CSF of healthy volunteers. J Pharmacol Exp Ther20, 116–157.
16.
SunZY, AsberomT, BaraT, BennettC, BurnettD, ChuI, CladerJ, Cohen-WilliamsM, ColeD, CzarnieckiM, DurkinJ, GalloG, GreenleeW, JosienH, HuangX, HydeL, JonesN, KazakevichI, LiH, LiuX, LeeJ, MaccossM, MandalMB, McCrackenT, NomeirA, MazzolaR, PalaniA, ParkerEM, PissarnitskiDA, QinJ, SongL, TerracinaG, VicarelM, VoigtJ, XuR, ZhangL, ZhangQ, ZhaoZ, ZhuX, ZhuZ (2012) Cyclic hydroxyamidines as amide isosteres: Discovery of oxadiazolines and oxadiazines as potent and highly efficacious γ-secretase modulators in vivo. J Med Chem55, 489–502.
17.
MillerDL, PotempskaA, MehtaP (2007) Humoral immune responses to peptides derived from the β-amyloid peptide C-terminal sequence. Amyloid14, 39–50.
18.
MillerDL, PotempskaA, WegielJ, MehtaP (2011) High-affinity rabbit monoclonal antibodies specific for amyloid peptides amyloid-β40 and β42. J Alzheimers Dis23, 293–305.
19.
FrackowiakJ, PotempskaA, Mazur-KoleckaB (2009) Formation of amyloid-β oligomers in brain vascular smooth muscle cells transiently exposed to iron-induced oxidative stress. Acta Neuropathol117, 557–567.
20.
IdaN, HartmannT, PantelJ, SchröderJ, ZerfassR, FörstlH, SandbrinkR, MastersCL, BeyreutherK (1996) Analysis of heterogeneous A4 peptides in human cerebrospinal fluid and blood by a newly developed sensitive western blot assay. J Biol Chem271, 22908–22914.
WegielJ, KuchnaI, NowickiK, FrackowiakJ, Mazur-KoleckaB, ImakiH, WegielJ, MehtaPD, SilvermanWP, ReisbergB, deLeonM, WisniewskiT, PirttillaT, FreyH, LehtimakiT, KivimakiT, VisserFE, KamphorstW, PotempskaA, BoltonD, CurrieJR, MillerDL (2007) Intraneuronal Aβ immunoreactivity is not a predictor of brain amyloidosis-β or neurofibrillary degeneration. Acta Neuropathol113, 389–402.
23.
KitamotoT, OgomoriK, TateishiJ, PrusinerSB (1987) Formic acid pretreatment enhances immunostaining of cerebral and systemic amyloids. Lab Invest57, 230–236.
24.
MehtaPD, PatrickB, BarshatzkyM, MehtaSP, FrackowiakJ, Mazur-KoleckaB, MillerDL (2015) Generation of rabbit monoclonal antibody to amyloid-β38: Increased plasma Aβ38 levels in Down syndrome. J Alzheimers Dis46, 1021–1032.
25.
SchoonenboomN, MulderC, Van KampGJ, MehtaSP, ScheltensP, BlankensteinMA, MehtaPD (2005) Aβ38, Aβ40 and Aβ42 species in cerebrospinal fluid: More of the same?. Ann Neurol58, 139–142.
26.
ThalDR, Capetillo-ZarateE, Del TrediciK, BraakH (2006) The development of amyloid beta protein deposits in the aged brain. Sci Aging Knowledge Envior6, re1.
27.
De StrooperB (2003) Aph-1, Pen-2, and nicastrin with presenilin generate an active gamma-secretase complex. Neuron38, 9–12.
28.
ObersteinTJ, SpitzerP, KlafkiH-W, LinningP, NeffF, KnölkerH-J, LewczukP, WiltfangJ, KornhuberJ, MalerJM (2015) Astrocytes and microglia but not neurons preferentially generate N-terminally truncated Aβ peptides. Neurobiol Dis73, 24–35.
29.
WegielJ, WisniewskiHM (1992) Projections of neurons in neuritic plaques formation. NeuroScience News2, 33–37.
30.
WisniewskiHM, WegielJ (1994) β-Amyloid formation by myocytes of leptomeningeal vessels. Acta Neuropathol87, 233–241.
31.
WisniewskiHM, WegielJ (1991) Spatial relationships between astrocytes and classical plaque components. Neurobiol Aging12, 593–600.
32.
ReinertJ, RichardBC, KlafkiHW, FriedrichB, BayerTA, WiltfangJ, KovacsGG, IngelssonM, LannfeltL, PaetauA, BergquistJ, WirthsO (2016) Deposition of C-terminally truncated Aβ species Aβ37 and Aβ39 in Alzheimer’s disease and transgenic mouse models. Acta Neuropathol Communn4, 24–43.
